|
ɽÂê¡§ÂèÆóÀ¤Âå¹³Àº¿ÀÉÂÌô¤Ø¤ÎÊѹ¹¤Ë¤è¤ë¿´·ì´É·Ï¥ê¥¹¥¯¾å¾º ÌÜŪ¡§Åý¹ç¼ºÄ´¾É¤¢¤ë¤¤¤ÏÅý¹ç¼ºÄ´´¶¾ð¾ã³²¤Ë¤ª¤¤¤Æ¡¢Ä¹´üÅêÍ¿¤Ë¤è¤ë¿´·ì´É·Ï¤Ø¤Îͳ²È¿±þ¤òÌÀ¤é¤«¤Ë¤¹¤ë¡£ ÊýË¡¡§1985ǯ¤«¤é2004ǯ¤Þ¤Ç¤ÎÈóÄê·¿¹³Àº¿ÀÉÂÌô¤Ë¤Ä¤¤¤Æ¡¢PubMed¤Ë¤è¤ê¡¢atypical antipsychotics, obesity, weight, diabetes mellitus, dyslipidemia, hypercholesterolemia, lipids, second generation antipsychotics, antipsychotic agents, schizophrenia, metabolic syndrome, cardiovascular disease, and cardiovascular risk factors¤ò¥¡¼¥ï¡¼¥É¤È¤·¤Æ¸¡º÷¡£ÆÀ¤é¤ì¤¿Ê¸¸¥¤òÉ®¼Ô¤é¤¬Àººº¡£ ·ë²Ì¡Ê¥Ç¡¼¥¿¤ÎÅý¹ç¡Ë¡§ÌôºÞ¤ÎÁªÂò¤Ï´µ¼Ô¤Ø¤Î¼£ÎŸú²Ì¤ò´ð½à¤ËÁªÂò¤µ¤ì¤ë¤Ù¤¤Ç¤¢¤ë¡£¤¿¤À¡¢£²¤Ä¤ÎÌôºÞ¤Î¼£ÎŸú²Ì¤¬Æ±¤¸¤Ê¤é¡¢Â¾¤ÎÎ×¾²¾å¤Î°ÕµÁ¤Ë¤è¤êÌôºÞ¤ÎÁªÂò¤¬¤Ê¤µ¤ì¤Æ¤â¤è¤¤¡£¥ª¥é¥ó¥¶¥Ô¥ó¤ä¥¯¥í¥¶¥Ô¥ó¤«¤é¥ê¥¹¥Ú¥ê¥É¥ó¤ËÊѹ¹¤Ç¿´·ì´É·Ï¤Î¥ê¥¹¥¯¤¬33¡ó¸º¾¯¡ÊµÕ¤Ê¤éƱΨÁý²Ã¡Ë¤¹¤ë¡£ ¤Þ¤È¤á¡§ÂèÆóÀ¤Âå¤ÎÌôºÞ¤ÎÁªÂò¤Ë¤è¤ê¿´·ì´É·Ï¤Î¥ê¥¹¥¯¤Ï°Û¤Ê¤ë¤¬¡¢ÌôºÞ¤òÊѹ¹¤·¤¿¾ì¹ç¤Î±Æ¶Á¤Ë¤Ä¤¤¤Æ¸ÀµÚ¤Ç¤¤ë¤Û¤É¥Ç¡¼¥¿¤ÏÃßÀѤµ¤ì¤Æ¤¤¤Ê¤¤¡£Á°¸þ¤¸¦µæ¤¬É¬Íס£ Êó¹ðÃÏ¡§University of Florida, Gainesville ½Ðŵ¡§Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM. , Increased cardiovascular risk with second-generation antipsychotic agent switches. J Am Pharm Assoc (Wash DC). 2006 Jul-Aug;46(4):491-8; quiz 499-501. PMID¡§16913393 ¾¶Ï¿¤Î¤ß¡£ ¥ª¥é¥ó¥¶¥Ô¥ó¤Ï¡¢¤È¤Æ¤â¤¤¤¤Ìô¤Ç¡¢ÉþÍѤ·¤ÆÍî¤ÁÃ夤¤¿¡¢¤È¤¤¤¦´µ¼Ô¤µ¤ó¤â¿¤¤¡£¤¿¤À¡¢ÅüǢɤòͶȯ¤¹¤ë¾ì¹ç¤¬¤¢¤ë¤È¤¤¤¦°ìÅÀ¤Ç¡¢»È¤¤¤Å¤é¤¤¤È¤³¤í¤¬¤¢¤ë¡£ ¤³¤Î¤¿¤á¡¢¿ÇÎŤò¤·¤Æ¤¤¤Æ¡¢¤â¤·ÅüǢɤòͶȯ¤·¤¿¤é¡¢¤È¤¤¤¦É԰¤˶î¤é¤ì¤ë¤³¤È¤¬¤¢¤ë¡£ ·ìÅü¤¬¹â¤¤¤È¡¢»È¤¤¤¿¤¯¤Ê¤¯¤Ê¤ë¡£ ¤¿¤À¡¢´µ¼Ô¤µ¤ó¤Ë¤è¤Ã¤Æ¤Ï¡¢Â¾ºÞ¤ËÊѹ¹¤¹¤ë¤È¡¢¤È¤¿¤ó¤ËÉÔÄ´¤È¤Ê¤ëÊý¤â¡£ ¤½¤¦¤¤¤¦¤È¤¡¢º¤¤ë¡£ É԰¤½¤¦¤Ê´µ¼Ô¤µ¤ó¤ÎÁ°¤Ç¤Ï¡ÖÂç¾æÉספȸÀ¤¤Â³¤±¤ë¤·¤«¡¢¤Ê¤¤¤±¤ì¤É¡£ ÅüǢɤÎÏäΥ¢¥Õ¥£¥ê¥¨¡¼¥È¤Ë¤ª²Û»Ò²°¤µ¤ó¤Ê¤ó¤Æ¤É¤¦¤Ç¤·¤ç¤¦¡£ ¸ý¤ÈÀ³Ê¤¬°¤¤¤Î¤Ç¡¢¤¹¤ß¤Þ¤»¤ó¡£ |
F2¡ÊÅý¹ç¼ºÄ´¾É¤Ê¤É¡Ë
[ ¥ê¥¹¥È | ¾ÜºÙ ]
Á´1¥Ú¡¼¥¸
[1]
|
ɽÂê¡§21ǯ´Ö¤Î·Ð²á´Ñ»¡¤Ë¤è¤ê¡¢Àº¿À²Ê¼õ¿Ç¤·¤¿¾®»ù´µ¼Ô¤Î¾®»ù´ü¤ÎIQ¤Ï¡¢¤Î¤Á¤ËÅý¹ç¼ºÄ´¾É¤È¤Ê¤Ã¤¿¾ì¹ç¤Î·ë²Ì¤òͽ¸«¤¹¤ë¡ÊActa Psychiatr Scand. 2002 Aug;106(2):139-42¡Ë ÌÜŪ¡§Åý¹ç¼ºÄ´¾É¤òȯ¾É¤¹¤ëÁ°¤ËÀº¿À²Ê¼õ¿Ç¤·¤¿»ùƸ¤Ï¡¢¤Î¤Á¤ËÀº¿Àɤ˿®¶Ä¤·¤Æ¤·¤Þ¤Ã¤¿¾ì¹ç¡¢ÆÃ¤Ë°°Õ¤Î¤¢¤ëɤËÃͤ¹¤ë¤È¤â¤¤¤¨¤ë¡£¤½¤ì¤é¤Î»ùƸ¤Î21ǯ¸å¤Î·ë²Ì¤Ë¤Ä¤¤¤ÆÄ´ºº¤ò¹Ô¤Ã¤¿¡£ ÊýË¡¡§Àº¿À²Ê¼õ¿Ç¤·¡¢¤Î¤Á¤ËÅý¹ç¼ºÄ´¾É¤È¿ÇÃǤµ¤ì¤¿»ùƸ51Îã¤ò¡¢Ê¿¶Ñ21ǯ¡¢·Ð²á´Ñ»¡»ë¤·¤¿¡£¾®»ù´ü¤Î¿Í¸ýưÂÖŪ¡¢Î×¾²Åª¡¢¤Þ¤¿ÁÛÄꤵ¤ì¤ëɰøÏÀ¤Ë¤è¤ëÆÃħ¤ò¡¢¿ÇÎÅÏ¿¤«¤é¸¡Æ¤¤·¤¿¡£Î×¾²¾å¤Îħ¸õ¡¢¼Ò²ñµ¡Ç½¤È¥µ¡¼¥Ó¥¹ÍøÍѾõ¶·¤ò·Ð²á´Ñ»¡¤·¤¿¡£Í½Â¬¤Ë±Æ¶Á¤·¤½¤¦¤Ê°ø»Ò¤ò¸¡Æ¤¤·¤¿¡£ ·ë²Ì¡§·ë²Ì¤ÏÉÔÎɤǤ¢¤ê¡¢7Îã¡Ê14¡ó¡Ë¤Ï»àË´¤·¤Æ¤¤¤¿¡£¾®»ù´ü¤ÎIQ¤Ï¼Ò²ñŬ±þ¾õ¶·(F=5.1, P=0.01)¤È¥µ¡¼¥Ó¥¹ÍøÍѾõ¶· (F=5.2, P=0.01)¤ò¶¯ÎϤËͽ¬¤·¤Æ¤¤¤¿¤¬¡¢Î×¾²Ä§¸õ¤È¤Ï´Ø·¸¤¬¤Ê¤«¤Ã¤¿¡£Â¾¤Î°ø»Ò¤Ï̵´Ø·¸¤Ç¤¢¤Ã¤¿¡£ ¤Þ¤È¤á¡§¾®»ù´ü¤ÎÄ㤤IQ¤Ï¡¢¤Ò¤È¤¿¤ÓÅý¹ç¼ºÄ´¾É¤¬È¯¾É¤·¤¿¾ì¹ç¡¢¼Ò²ñŬ±þ¾õ¶·¤È¥µ¡¼¥Ó¥¹ÍøÍѾõ¶·¤Ë¤Ä¤¤¤Æ¡¢¹¥¤Þ¤·¤¯¤Ê¤¤±Æ¶Á¤¬¤¢¤ë¡£ Êó¹ðÃÏ¡§London¡¤UK ½Ðŵ¡§Munro JC, Russell AJ, Murray RM, Kerwin RW, Jones PB. IQ in childhood psychiatric attendees predicts outcome of later schizophrenia at 21 year follow-up. Acta Psychiatr Scand. 2002 Aug;106(2):139-42. PMID¡§12121212 ¡¡´¶ÁÛ ¡¡ºòÆü¡¢ID12121211¤Îµ»ö¤òÆÉ¤ó¤À¤Î¤Ç¡¢¥¥êÈÖ¤òÆÉ¤ó¤Ç¤ß¤¿¡£·ÇºÜ¤Ï¸åÆü¤Ë¤·¤è¤¦¤«¤È»×¤Ã¤¿¤¬¡¢Åöľ¤Ê¤Î¤Ç¡¢¤³¤Ã¤Á¤Ë¤·¤¿¡£ ¡¡Åý¹ç¼ºÄ´¾É¤ÈÀº¿ÀÃÙÂڤιçÊ»Îã¤Ç¡¢Åý¹ç¼ºÄ´¾Éȯ¾É¸å¤Ë¡¢¼Ò²ñŬ±þ¾õ¶·¤Ë¤«¤Ê¤ê°±Æ¶Á¤¬¤¢¤ë¤È¤¤¤¦¤Î¤Ï¡¢¤½¤ÎÄ̤ê¤À¤È»×¤¦¡£ ¡¡Àº¿ÀÃÙÂÚ¤Îͽ¸å¤Ë¤Ä¤¤¤Æ¡¢»º¶È³×Ì¿Á°¡¢ÆüËܤλº¶È³×Ì¿Á°¤Ç¤â¤¤¤¤¤Î¤À¤¬¡¢¤¿¤È¤¨¤Ð¹¾¸Í»þÂå¤Ë¤ÏÇÀ¶È¤È¤¤¤¦°ìÄê¤Î¿¦¤¬¤¢¤Ã¤Æ¡¢¤½¤ì¤ò¤ä¤Ã¤Æ¤¤¤ì¤Ð¤è¤«¤Ã¤¿¡¢Â¼Íî¤Ç狼¤¬½õ¤±¤Æ¤¯¤ì¤Æ¤¤¤¿¤Î¤Ç¡¢º£¤Û¤É¡¢»Ù±ç¤«¤éÈ´¤±Íî¤Á¤Æ¤·¤Þ¤¦¤³¤È¤Ï¤Ê¤«¤Ã¤¿¡¢¤È¤¤¤¦ÀâÌÀ¤¬¤Ê¤µ¤ì¤ë¤³¤È¤¬¤¢¤ë¡£ ¡¡¤½¤¦¤¤¤¦¤Î¤Ê¤é¡¢¤½¤¦¤Ê¤Î¤À¤í¤¦¡£ ¡¡¤Ç¤â¡¢¿©ÎÈÀ¸»º¤¬¸Â¤é¤ì¤ë¤È¤¤¤¦¸½¼Â¤ÎÀ©Ì󤬤¢¤ë¤¿¤á¤Ë¡¢¤è¤ê¼ÂÎϼçµÁ¤È¤Ê¤é¤¶¤ë¤ò¤¨¤Ê¤¤¡¢Æ¯¤«¤¶¤ë¼Ô¿©¤¦¤Ù¤«¤é¤º¡¢¤È¤¤¤¦»þÂå¡¢ËÜÅö¤Ë¤½¤¦¤À¤Ã¤¿¤Î¤À¤í¤¦¤«¡£ ¡¡¤½¤ó¤Ê¿Í¤â¤¤¤ë¤À¤í¤¦¤±¤É¡¢»Ä¤ê¤Ï¡Ö¤¢¤Ã¤µ¤ê¡¢»à¤ó¤Ç¤¿¤ó¤¸¤ã¤Ê¤¤¤Î¡©¡×¤È¤â¹Í¤¨¤Æ¤·¤Þ¤¦¡£ |
Á´1¥Ú¡¼¥¸
[1]


